These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19715403)

  • 21. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
    Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
    Heiber JF; Barber GN
    J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
    Escobar-Zarate D; Liu YP; Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2013 Oct; 20(10):582-9. PubMed ID: 24030211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
    Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
    J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
    Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
    J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.
    Randle RW; Northrup SA; Sirintrapun SJ; Lyles DS; Stewart JH
    Surgery; 2013 Dec; 154(6):1323-29; discussion 1329-30. PubMed ID: 23973113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
    Betancourt D; Ramos JC; Barber GN
    J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
    Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
    Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
    Moon J; Kaowinn S; Cho IR; Min DS; Myung H; Oh S; Kaewpiboon C; Kraemer OH; Chung YH
    Biochem Biophys Res Commun; 2016 Jun; 474(3):428-434. PubMed ID: 27150631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
    Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
    J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
    Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
    Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3.
    Marozin S; Altomonte J; Stadler F; Thasler WE; Schmid RM; Ebert O
    Mol Ther; 2008 Nov; 16(11):1789-97. PubMed ID: 18781139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vesiculovirus neutralization by natural IgM and complement.
    Tesfay MZ; Ammayappan A; Federspiel MJ; Barber GN; Stojdl D; Peng KW; Russell SJ
    J Virol; 2014 Jun; 88(11):6148-57. PubMed ID: 24648451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A confocal and electron microscopic comparison of interferon beta-induced changes in vesicular stomatitis virus infection of neuroblastoma and nonneuronal cells.
    D'Agostino PM; Reiss CS
    DNA Cell Biol; 2010 Mar; 29(3):103-20. PubMed ID: 20113203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
    Fehl DJ; Ahmed M
    Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.
    van den Pol AN; Davis JN
    J Virol; 2013 Jan; 87(2):1019-34. PubMed ID: 23135719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
    Silberhumer GR; Brader P; Wong J; Serganova IS; Gönen M; Gonzalez SJ; Blasberg R; Zamarin D; Fong Y
    Mol Cancer Ther; 2010 Oct; 9(10):2761-9. PubMed ID: 20858727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.
    Wollmann G; Robek MD; van den Pol AN
    J Virol; 2007 Feb; 81(3):1479-91. PubMed ID: 17108037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.